T. Rowe Price Health Sciences
Category: Health Care
Fund Return for 2012: 35.18%
Category Return for 2012: 22%
Assets Under Management: $4.8 billion
Health care already tends to be a stable business, and the huge demographic shift of advancing boomers in the U.S. — not to mention aging populations in Europe and parts of Asia — make the sector’s long-term prospects look even brighter.
One fund that hasn’t had to wait for the long-term, though, is the T. Rowe Price Health Sciences Fund (MUTF:PRHSX). A key reason is its focus on smaller companies, which have the opportunity for huge upside thanks to breakout drugs and treatments. Some of the fund’s holdings include Pharmacyclics (NASDAQ:PCYC), Incyte (NASDAQ:INCY) and Regeneron Pharmaceuticals (NASDAQ:REGN).
PRHSX also has posted a strong long-term track record, returning 14.76% annually for the past 10 years.
Health Sciences is a no-load fund that charges 0.82% in expenses and requires a $2,500 minimum investment.